US Generic Drug Submission Boost May Dampen New Approval Record
This article was originally published in SRA
The US Food and Drug Administration's improved generic drug approval performance may face increasing pressure if submission volume continues to increase.
You may also be interested in...
CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.
The US FDA appears to have concerns about the device used to administer the vaccine.
The US Medicare agency has released a quick-start guide for laboratory certification.